CIZZLE BIOTECHNOLOGY HOLDINGS PLC Logo

CIZZLE BIOTECHNOLOGY HOLDINGS PLC

Developing a CIZ1B biomarker blood test for the early detection of lung cancer.

CIZ | IL

Overview

Corporate Details

ISIN(s):
GB00BNG2VN02
LEI:
213800G3OS3SA2J1Y358
Country:
United Kingdom
Address:
6TH FLOOR, 60 GRACECHURCH STREET, EC3V 0HR LONDON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Cizzle Biotechnology Holdings PLC is a diagnostics company developing a non-invasive blood test for the early detection of lung cancer. The company's core product utilizes its proprietary CIZ1B biomarker, an advanced immunoassay designed to identify lung cancer at its earliest, most treatable stages with high sensitivity. This cost-effective solution aims to streamline the diagnostic pathway for healthcare providers, reducing reliance on CT scans and minimizing unnecessary invasive follow-up procedures. Originating as a spin-out from the University of York, Cizzle is advancing its technology through global clinical trials to secure regulatory approval and improve patient outcomes worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-05 08:35
Capital/Financing Update
£250,000 Convertible Loan Note Issue
English 16.3 KB
2025-11-05 08:20
Regulatory News Service
LOI with leading UK Clinical Diagnostic Group
English 16.3 KB
2025-09-29 08:00
Regulatory News Service
Update on Clinical Laboratory Partnerships in USA
English 22.2 KB
2025-08-18 08:00
Regulatory News Service
Commercial Progress in USA
English 22.0 KB
2025-07-08 10:40
Annual Report
Annual Report for the year ended 31 December 2024
English 332.7 KB
2025-06-06 12:00
Report Publication Announcement
Notice of AGM
English 11.4 KB
2025-05-28 08:00
Major Shareholding Notification
Holding(s) in Company
English 51.1 KB
2025-03-25 08:00
Board/Management Information
Appointment of Non-Executive Director
English 15.7 KB
2025-01-02 08:00
Board/Management Information
Appointment of Professor Dawn Coverley as CSO
English 17.8 KB
2024-12-16 08:00
M&A Activity
Update on Strategic Partnership in North America
English 23.8 KB
2024-10-21 08:00
M&A Activity
Execution of Agreement for North America
English 25.9 KB
2024-10-03 14:12
Regulatory News Service
Update on Licensing and Partnership Agreement
English 10.6 KB
2024-09-30 08:00
Interim Report
Interim Results
English 208.3 KB
2024-09-16 08:00
Major Shareholding Notification
Holding(s) in Company
English 37.5 KB
2024-09-09 08:00
Regulatory News Service
Collaboration with Moffitt Cancer Center
English 25.0 KB

Automate Your Workflow. Get a real-time feed of all CIZZLE BIOTECHNOLOGY HOLDINGS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CIZZLE BIOTECHNOLOGY HOLDINGS PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CIZZLE BIOTECHNOLOGY HOLDINGS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.